{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:24:26Z","timestamp":1794367466672,"version":"4.9.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Induction of EBV lytic-phase gene expression, combined with exposure to an antiherpes viral drug, represents a promising targeted therapeutic approach to EBV-associated lymphomas. Short-chain fatty acids or certain chemotherapeutics have been used to induce EBV lytic-phase gene expression in cultured cells and mouse models, but these studies generally have not translated into clinical application. The recent success of a clinical trial with the pan-histone deacetylase (pan-HDAC) inhibitor arginine butyrate and the antiherpes viral drug ganciclovir in the treatment of EBV lymphomas prompted us to investigate the potential of several HDAC inhibitors, including some new, highly potent compounds, to sensitize EBV+ human lymphoma cells to antiviral agents in vitro. Our study included short-chain fatty acids (sodium butyrate and valproic acid); hydroxamic acids (oxamflatin, Scriptaid, suberoyl anilide hydroxamic acid, panobinostat [LBH589], and belinostat [PXD101]); the benzamide MS275; the cyclic tetrapeptide apicidin; and the recently discovered HDAC inhibitor largazole. With the exception of suberoyl anilide hydroxamic acid and PXD101, all of the other HDAC inhibitors effectively sensitized EBV+ lymphoma cells to ganciclovir. LBH589, MS275, and largazole were effective at nanomolar concentrations and were 104 to 105 times more potent than butyrate. The effectiveness and potency of these HDAC inhibitors make them potentially applicable as sensitizers to antivirals for the treatment of EBV-associated lymphomas.<\/jats:p>","DOI":"10.1182\/blood-2011-06-362434","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T01:39:27Z","timestamp":1323394767000},"page":"1008-1017","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":144,"title":["Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents"],"prefix":"10.1182","volume":"119","author":[{"given":"Sajal K.","family":"Ghosh","sequence":"first","affiliation":[{"name":"Cancer Center, Boston University School of Medicine, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Perrine","sequence":"additional","affiliation":[{"name":"Cancer Center, Boston University School of Medicine, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Colorado State University, Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[{"name":"Cancer Center, Boston University School of Medicine, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809125572100_B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7326\/0003-4819-118-1-199301010-00009","article-title":"NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.","volume":"118","author":"Straus","year":"1993","journal-title":"Ann Intern Med"},{"key":"2019111809125572100_B2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma.","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"issue":"3","key":"2019111809125572100_B3","first-page":"376","article-title":"Nasopharyngeal carcinoma: the Epstein-Barr virus association.","volume":"21","author":"Liebowitz","year":"1994","journal-title":"Semin Oncol"},{"issue":"4","key":"2019111809125572100_B4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jcp.53.4.248","article-title":"The role of EBV in post-transplant malignancies: a review.","volume":"53","author":"Hopwood","year":"2000","journal-title":"J Clin Pathol"},{"issue":"2","key":"2019111809125572100_B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.177.2.339","article-title":"Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.","volume":"177","author":"Deacon","year":"1993","journal-title":"J Exp Med"},{"issue":"8","key":"2019111809125572100_B6","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V81.8.2102.2102","article-title":"Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus.","volume":"81","author":"Shibata","year":"1993","journal-title":"Blood"},{"issue":"16","key":"2019111809125572100_B7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jnci\/91.16.1376","article-title":"Detection of Epstein-Barr virus in invasive breast cancers.","volume":"91","author":"Bonnet","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2019111809125572100_B8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/00000478-199411000-00010","article-title":"In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas.","volume":"18","author":"Yuen","year":"1994","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111809125572100_B9","first-page":"969","article-title":"Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia.","volume":"56","author":"Guti\u00e9rrez","year":"1996","journal-title":"Cancer Res"},{"issue":"3","key":"2019111809125572100_B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1034\/j.1399-3062.2001.003003177.x","article-title":"Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.","volume":"3","author":"Mentzer","year":"2001","journal-title":"Transpl Infect Dis"},{"issue":"33","key":"2019111809125572100_B11","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1038\/sj.onc.1206548","article-title":"Virally targeted therapies for EBV-associated malignancies.","volume":"22","author":"Israel","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"2019111809125572100_B12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"issue":"20","key":"2019111809125572100_B13","first-page":"5781","article-title":"Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.","volume":"60","author":"Westphal","year":"2000","journal-title":"Cancer Res"},{"issue":"7","key":"2019111809125572100_B14","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1128\/AAC.45.7.2082-2091.2001","article-title":"Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.","volume":"45","author":"Moore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2019111809125572100_B15","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1128\/JVI.79.9.5875-5879.2005","article-title":"Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.","volume":"79","author":"Daibata","year":"2005","journal-title":"J Virol"},{"issue":"4","key":"2019111809125572100_B16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","article-title":"Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.","volume":"78","author":"Feng","year":"2004","journal-title":"J Virol"},{"issue":"10","key":"2019111809125572100_B17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.1864","article-title":"Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.","volume":"14","author":"Fu","year":"2008","journal-title":"Nat Med"},{"issue":"6","key":"2019111809125572100_B18","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111809125572100_B19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/hmg\/10.7.693","article-title":"Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.","volume":"10","author":"Wade","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"18","key":"2019111809125572100_B20","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1128\/MCB.21.18.6091-6101.2001","article-title":"The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3.","volume":"21","author":"Guenther","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2019111809125572100_B21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code.","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2019111809125572100_B22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bcp.2004.05.034","article-title":"Histone deacetylase inhibitors open new doors in cancer therapy.","volume":"68","author":"McLaughlin","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"2019111809125572100_B23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.","volume":"3","author":"Tan","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2019111809125572100_B24","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors.","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111809125572100_B25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"7","key":"2019111809125572100_B26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2019111809125572100_B27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.1.5.1045-1051.1967","article-title":"Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.","volume":"1","author":"Hinuma","year":"1967","journal-title":"J Virol"},{"issue":"7","key":"2019111809125572100_B28","first-page":"1300","article-title":"Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.","volume":"28","author":"Klein","year":"1968","journal-title":"Cancer Res"},{"issue":"3","key":"2019111809125572100_B29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1073\/pnas.73.3.910","article-title":"Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations.","volume":"73","author":"Terhorst","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111809125572100_B30","first-page":"276","article-title":"Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.","volume":"22","author":"Menezes","year":"1975","journal-title":"Biomedicine"},{"issue":"3","key":"2019111809125572100_B31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0609.1999.tb01766.x","article-title":"Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines.","volume":"63","author":"Gabay","year":"1999","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111809125572100_B32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/ol900078k","article-title":"Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.","volume":"11","author":"Bowers","year":"2009","journal-title":"Org Lett"},{"issue":"1","key":"2019111809125572100_B33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcmd.2006.10.008","article-title":"Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.","volume":"38","author":"Ghosh","year":"2007","journal-title":"Blood Cells Mol Dis"},{"issue":"26","key":"2019111809125572100_B34","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1021\/ja8013727","article-title":"Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.","volume":"130","author":"Ying","year":"2008","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2019111809125572100_B35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JVI.46.1.187-195.1983","article-title":"Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity.","volume":"46","author":"Ooka","year":"1983","journal-title":"J Virol"},{"issue":"9","key":"2019111809125572100_B36","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.","volume":"84","author":"Meng","year":"2010","journal-title":"J Virol"},{"key":"2019111809125572100_B37","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2741\/2000","article-title":"Epstein-Barr virus (EBV) and its associated human cancers\u2013genetics, epigenetics, pathobiology and novel therapeutics.","volume":"11","author":"Tao","year":"2006","journal-title":"Front Biosci"},{"issue":"11","key":"2019111809125572100_B38","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/AAC.42.11.2923","article-title":"The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.","volume":"42","author":"Gustafson","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2019111809125572100_B39","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood.V114.22.4754.4754","article-title":"Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas [abstract].","volume":"114","author":"Faller","year":"2009","journal-title":"Blood"},{"issue":"18 pt 1","key":"2019111809125572100_B40","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-07-0791","article-title":"Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.","volume":"13","author":"Kummar","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7-8","key":"2019111809125572100_B41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2013the development of an anticancer agent.","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2019111809125572100_B42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","article-title":"A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.","volume":"66","author":"Rathkopf","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2019111809125572100_B43","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1128\/JVI.61.10.3120-3132.1987","article-title":"Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells.","volume":"61","author":"Biggin","year":"1987","journal-title":"J Virol"},{"issue":"4","key":"2019111809125572100_B44","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/j.1460-2075.1984.tb01890.x","article-title":"The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus.","volume":"3","author":"Jones","year":"1984","journal-title":"EMBO J"},{"issue":"21-22","key":"2019111809125572100_B45","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.lfs.2008.03.004","article-title":"The use of diversity profiling to characterize chemical modulators of the histone deacetylases.","volume":"82","author":"Blackwell","year":"2008","journal-title":"Life Sci"},{"issue":"3","key":"2019111809125572100_B46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases.","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2019111809125572100_B47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF01989417","article-title":"Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.","volume":"49","author":"Perrine","year":"1993","journal-title":"Experientia"},{"issue":"11","key":"2019111809125572100_B48","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1128\/JVI.72.11.9150-9156.1998","article-title":"Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.","volume":"72","author":"Komano","year":"1998","journal-title":"J Virol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/4\/1008\/1354441\/zh800412001008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/4\/1008\/1354441\/zh800412001008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T14:13:33Z","timestamp":1593353613000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/4\/1008\/29689\/Histone-deacetylase-inhibitors-are-potent-inducers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,1,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-362434","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,26]]}}}